脳脊髄炎の世界市場レポート 2025年

脳脊髄炎市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.7％で293億1,000万米ドルに成長します。この予測期間における成長は、免疫療法治療の採用の増加、自己免疫疾患の有病率の上昇、ヘルスケア支出の増加、臨床研究の拡大、脳脊髄炎に対する認識と教育の高まりに起因しています。さらに、希少疾患研究に対する政府と民間の資金提供の増加も重要な役割を果たすと考えられます。予測期間における主要動向としては、先進的な免疫調節療法の開発、精密生物製剤の進歩、早期診断のための新規バイオマーカー、個別化治療の進展、次世代抗ウイルス薬の創出、臨床研究におけるAIの統合、革新的な遺伝子治療アプローチなどが挙げられます。

自己免疫疾患の有病率の増加は、今後数年間の脳脊髄炎市場の成長を牽引すると予想されます。自己免疫疾患は、身体の免疫系が誤って自身の健康な細胞や組織を攻撃する疾患です。自己免疫疾患の増加は、遺伝的素因、環境的誘因、感染症、食事や化学品への暴露を含むライフスタイルの変化などの要因によるところが大きいです。脳脊髄炎治療は、炎症を抑え、免疫系の機能不全を管理し、神経症状を緩和し、病気の進行を予防することで、自己免疫疾患患者を助ける。これにより、最終的には患者のQOL（生活の質）と機能的幸福が向上します。例えば、2024年11月、ドイツを拠点とする団体Versorgungsatlas.deは、2022年、7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断され、その結果、生の有病率は8.61％となったと報告しました。したがって、自己免疫疾患の罹患率の上昇が脳脊髄炎市場の成長を牽引しています。

脳脊髄炎市場で事業を展開する企業は、治療効果を高め、脳脊髄炎を管理するための標的療法を開発するために、先進的なモノクローナル抗体療法の開発に注力しています。モノクローナル抗体は、病気に対する免疫反応を助けるために特定の抗原に結合する人工的に作られたタンパク質です。例えば、2023年3月、日本の製薬会社である中外製薬株式会社は、「モノクローナル抗体」を開発しました。日本の製薬会社である中外製薬株式会社は、ヒト化抗IL-6レセプターモノクローナル抗体Enspryngが、ミエリンオリゴデンドロサイト糖タンパク質抗体関連疾患（MOGAD）と自己免疫性脳炎（AIE）の治療として厚生労働省から先駆け指定を受けたと発表しました。この指定により、革新的な治療としてのエンスプライグの可能性が認められ、これらの神経疾患患者のアンメット・メディカル・ニーズに対応するための開発と承認審査が加速されることになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の脳脊髄炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の脳脊髄炎市場：成長率分析
• 世界の脳脊髄炎市場の実績：規模と成長、2019～2024年
• 世界の脳脊髄炎市場の予測：規模と成長、2024～2029年、2034年
• 世界の脳脊髄炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脳脊髄炎市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 馬脳脊髄炎
• 関連脳脊髄炎
• 抗ミエリンオリゴデンドロサイト糖タンパク質抗体（抗MOG）
• 脳脊髄炎ディスセミナタ
• 急性散在性脳脊髄炎
• エイズ関連脳脊髄炎
• その他
• 世界の脳脊髄炎市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 手術
• 血漿交換
• 薬剤治療
• その他
• 世界の脳脊髄炎市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• クリニック
• 病院
• その他
• 世界の脳脊髄炎市場、馬脳脊髄炎のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 東部馬脳脊髄炎
• 西部馬脳脊髄炎
• ベネズエラ馬脳脊髄炎
• 世界の脳脊髄炎市場、関連脳脊髄炎のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 急性散在性脳脊髄炎
• 腫瘍随伴性脳脊髄炎
• 感染性脳脊髄炎
• 世界の脳脊髄炎市場、抗ミエリンオリゴデンドロサイト糖タンパク質抗体のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 単相性ミエリンオリゴデンドロサイト糖タンパク質抗体脳脊髄炎
• 再発性ミエリンオリゴデンドロサイト糖タンパク質抗体脳脊髄炎
• 世界の脳脊髄炎市場、脳脊髄炎のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ウイルス性脳脊髄炎
• 細菌性脳脊髄炎
• 自己免疫脳脊髄炎

第7章 地域別・国別分析

• 世界の脳脊髄炎市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の脳脊髄炎市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脳脊髄炎市場：競合情勢
• 脳脊髄炎市場：企業プロファイル
  • Merck & Co. Inc.
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • HiFiBiO Therapeutics
  • Zoetis Services LLC

第31章 その他の大手企業と革新的企業

• Chugai Pharmaceutical Co. Ltd.
• IDEXX
• Abcam Limited.
• EUROIMMUN Medizinische Labordiagnostika AG
• Eurogentec S.A.
• Boehringer Ingelheim International GmbH
• Creative Diagnostics
• Atlas Antibodies
• AnaSpec
• VMRD Inc.
• Antibodies Incorporated
• Fresenius Kabi
• Hemispherx Biopharma Inc.
• BioStoneah
• YouSeq Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 脳脊髄炎市場、2029年：新たな機会を提供する国
• 脳脊髄炎市場、2029年：新たな機会を提供するセグメント
• 脳脊髄炎市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Encephalomyelitis refers to the inflammation of both the brain and spinal cord, typically caused by infections, immune system dysfunction, or other underlying medical conditions. This condition can lead to neurological problems, such as muscle weakness, paralysis, and cognitive disturbances.

The main types of encephalomyelitis include equine encephalomyelitis, associated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody (anti-MOG) encephalomyelitis, encephalomyelitis disseminata, acute disseminated encephalomyelitis, AIDS-related encephalomyelitis, and others. Equine encephalomyelitis is a viral disease affecting horses, caused by the eastern, western, or Venezuelan equine encephalitis viruses, leading to inflammation in the brain and spinal cord. Treatment options for encephalomyelitis include surgery, plasmapheresis, drug treatments, and other methods, and are utilized in various healthcare settings, including clinics and hospitals.

The encephalomyelitis market research report is one of a series of new reports from The Business Research Company that provides encephalomyelitis market statistics, including the encephalomyelitis industry's global market size, regional shares, competitors with a encephalomyelitis market share, detailed encephalomyelitis market segments, market trends and opportunities, and any further data you may need to thrive in the encephalomyelitis industry. This encephalomyelitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The encephalomyelitis market size has grown strongly in recent years. It will grow from $21.16 billion in 2024 to $22.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the increasing prevalence of autoimmune and infectious diseases, a rise in awareness regarding neurological disorders, greater investment in research and development, advancements in healthcare infrastructure, and the expanding applications of immunotherapy.

The encephalomyelitis market size is expected to see strong growth in the next few years. It will grow to $29.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to the increasing adoption of immunotherapy treatments, a rising prevalence of autoimmune disorders, growing healthcare expenditure, expanded clinical research, and greater awareness and education about encephalomyelitis. Additionally, the rising government and private funding for rare disease research will play a key role. Major trends in the forecast period include the development of advanced immunomodulatory therapies, advancements in precision biologics, novel biomarkers for early diagnosis, progress in personalized treatments, the creation of next-generation antivirals, the integration of AI in clinical research, and innovative gene therapy approaches.

The growing prevalence of autoimmune diseases is expected to drive the growth of the encephalomyelitis market in the coming years. Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own healthy cells and tissues. The rise in autoimmune diseases is largely attributed to factors such as genetic predisposition, environmental triggers, infections, and lifestyle changes, including diet and exposure to chemicals. Encephalomyelitis treatment helps autoimmune disease patients by reducing inflammation, managing immune system dysfunction, alleviating neurological symptoms, and preventing disease progression. This ultimately enhances their quality of life and functional well-being. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Therefore, the rising incidence of autoimmune diseases is driving the growth of the encephalomyelitis market.

Companies operating in the encephalomyelitis market are focusing on the development of advanced monoclonal antibody therapies to enhance treatment efficacy and create targeted therapies for managing encephalomyelitis. Monoclonal antibodies are artificially created proteins that bind to specific antigens to assist the immune response against diseases. For instance, in March 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, announced that its humanized anti-IL-6 receptor monoclonal antibody, Enspryng, received forerunner designation from the Ministry of Health, Labor and Welfare (MHLW) for its anticipated use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). This designation recognizes Enspryng's potential as an innovative treatment, accelerating its development and regulatory review to address the unmet medical needs of patients with these neurological conditions.

In January 2024, Zuellig Pharma Holdings Ltd., a Singapore-based hospital and healthcare company, partnered with Substipharm Biologics to enhance vaccine access. This partnership aims to improve the availability of the IMOJEV Japanese encephalitis vaccine across nine Asian markets, utilizing Zuellig Pharma's marketing, distribution, and ZP Therapeutics' expertise. Substipharm Biologics, a France-based pharmaceutical company, develops various vaccines, including those for encephalitis and encephalomyelitis.

Major players in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.

North America was the largest region in the encephalomyelitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in encephalomyelitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the encephalomyelitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The encephalomyelitis market consists of revenues earned by entities by providing services such as chest X-rays and CT scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The encephalomyelitis market also includes sales of antiviral therapy, and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Encephalomyelitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on encephalomyelitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for encephalomyelitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The encephalomyelitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Equine Encephalomyelitis; Associated Encephalomyelitis; Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG); Encephalomyelitis Disseminata; Acute Disseminated Encephalomyelitis; AIDS-Related Encephalomyelitis; Other Types
• 2) By Treatment: Surgery ; Plasmapheresis; Drug Treatment; Other Treatments
• 3) By End-users: Clinics ; Hospitals; Other End-Users
• Subsegments:
• 1) By Equine Encephalomyelitis: Eastern Equine Encephalomyelitis; Western Equine Encephalomyelitis; Venezuelan Equine Encephalomyelitis
• 2) By Associated Encephalomyelitis: Acute Disseminated Encephalomyelitis; Paraneoplastic Encephalomyelitis; Infectious Encephalomyelitis
• 3) By Anti-Myelin Oligodendrocyte Glycoprotein Antibody: Monophasic Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis; Relapsing Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis
• 4) By Encephalomyelitis: Viral Encephalomyelitis; Bacterial Encephalomyelitis; Autoimmune Encephalomyelitis
• Companies Mentioned: Merck & Co. Inc.; Sanofi S.A.; F. Hoffmann-La Roche Ltd.; HiFiBiO Therapeutics; Zoetis Services LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Encephalomyelitis Market Characteristics

3. Encephalomyelitis Market Trends And Strategies

4. Encephalomyelitis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Encephalomyelitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Encephalomyelitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Encephalomyelitis Market Growth Rate Analysis
• 5.4. Global Encephalomyelitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Encephalomyelitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Encephalomyelitis Total Addressable Market (TAM)

6. Encephalomyelitis Market Segmentation

• 6.1. Global Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Equine Encephalomyelitis
• Associated Encephalomyelitis
• Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG)
• Encephalomyelitis Disseminata
• Acute Disseminated Encephalomyelitis
• AIDS-Related Encephalomyelitis
• Other Types
• 6.2. Global Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Plasmapheresis
• Drug Treatment
• Other Treatments
• 6.3. Global Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Other End-Users
• 6.4. Global Encephalomyelitis Market, Sub-Segmentation Of Equine Encephalomyelitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eastern Equine Encephalomyelitis
• Western Equine Encephalomyelitis
• Venezuelan Equine Encephalomyelitis
• 6.5. Global Encephalomyelitis Market, Sub-Segmentation Of Associated Encephalomyelitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Disseminated Encephalomyelitis
• Paraneoplastic Encephalomyelitis
• Infectious Encephalomyelitis
• 6.6. Global Encephalomyelitis Market, Sub-Segmentation Of Anti-Myelin Oligodendrocyte Glycoprotein Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monophasic Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis
• Relapsing Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis
• 6.7. Global Encephalomyelitis Market, Sub-Segmentation Of Encephalomyelitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Encephalomyelitis
• Bacterial Encephalomyelitis
• Autoimmune Encephalomyelitis

7. Encephalomyelitis Market Regional And Country Analysis

• 7.1. Global Encephalomyelitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Encephalomyelitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Encephalomyelitis Market

• 8.1. Asia-Pacific Encephalomyelitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Encephalomyelitis Market

• 9.1. China Encephalomyelitis Market Overview
• 9.2. China Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Encephalomyelitis Market

• 10.1. India Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Encephalomyelitis Market

• 11.1. Japan Encephalomyelitis Market Overview
• 11.2. Japan Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Encephalomyelitis Market

• 12.1. Australia Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Encephalomyelitis Market

• 13.1. Indonesia Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Encephalomyelitis Market

• 14.1. South Korea Encephalomyelitis Market Overview
• 14.2. South Korea Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Encephalomyelitis Market

• 15.1. Western Europe Encephalomyelitis Market Overview
• 15.2. Western Europe Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Encephalomyelitis Market

• 16.1. UK Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Encephalomyelitis Market

• 17.1. Germany Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Encephalomyelitis Market

• 18.1. France Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Encephalomyelitis Market

• 19.1. Italy Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Encephalomyelitis Market

• 20.1. Spain Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Encephalomyelitis Market

• 21.1. Eastern Europe Encephalomyelitis Market Overview
• 21.2. Eastern Europe Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Encephalomyelitis Market

• 22.1. Russia Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Encephalomyelitis Market

• 23.1. North America Encephalomyelitis Market Overview
• 23.2. North America Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Encephalomyelitis Market

• 24.1. USA Encephalomyelitis Market Overview
• 24.2. USA Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Encephalomyelitis Market

• 25.1. Canada Encephalomyelitis Market Overview
• 25.2. Canada Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Encephalomyelitis Market

• 26.1. South America Encephalomyelitis Market Overview
• 26.2. South America Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Encephalomyelitis Market

• 27.1. Brazil Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Encephalomyelitis Market

• 28.1. Middle East Encephalomyelitis Market Overview
• 28.2. Middle East Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Encephalomyelitis Market

• 29.1. Africa Encephalomyelitis Market Overview
• 29.2. Africa Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Encephalomyelitis Market Competitive Landscape And Company Profiles

• 30.1. Encephalomyelitis Market Competitive Landscape
• 30.2. Encephalomyelitis Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. HiFiBiO Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Zoetis Services LLC Overview, Products and Services, Strategy and Financial Analysis

31. Encephalomyelitis Market Other Major And Innovative Companies

• 31.1. Chugai Pharmaceutical Co. Ltd.
• 31.2. IDEXX
• 31.3. Abcam Limited.
• 31.4. EUROIMMUN Medizinische Labordiagnostika AG
• 31.5. Eurogentec S.A.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Creative Diagnostics
• 31.8. Atlas Antibodies
• 31.9. AnaSpec
• 31.10. VMRD Inc.
• 31.11. Antibodies Incorporated
• 31.12. Fresenius Kabi
• 31.13. Hemispherx Biopharma Inc.
• 31.14. BioStoneah
• 31.15. YouSeq Ltd.

32. Global Encephalomyelitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Encephalomyelitis Market

34. Recent Developments In The Encephalomyelitis Market

35. Encephalomyelitis Market High Potential Countries, Segments and Strategies

• 35.1 Encephalomyelitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Encephalomyelitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Encephalomyelitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer